NASDAQ · Medical - Diagnostics & Research

Insight Molecular Diagnostics Inc. (IMDX) Stock

$4.70 -0.84% NASDAQ: IMDX Healthcare

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories.

Valuation

MetricValue
Price$4.70
Market Cap$151.76M
P/E Ratio-3.13
P/B Ratio-15.30
P/S Ratio78.53
EPS (TTM)$-1.65
52-Week High$8.51
52-Week Low$2.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE380.80%
ROA-118.34%
ROCE-144.86%
Gross Margin-775.00%
Operating Margin-775.00%
Net Margin-24.55%
Debt/Equity-0.29
Current Ratio1.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$1.0M$2.0M$2.0M$4.0M
Operating Profit$-54.0M$-18.0M$-25.0M$-61.0M$-31.0M
Net Profit$-64.0M$-73.0M$-28.0M$-61.0M$-50.0M
EPS$-14.40$-20.00$-3.75$-4.66$-1.65
Op Margin-2444.3%-1878.6%-1672.4%-3245.1%-754.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$160.0M$100.0M$75.0M$35.0M$26.0M
Total Liabilities$94.0M$60.0M$54.0M$47.0M$57.0M
Cash$33.0M$20.0M$9.0M$9.0M$12.0M
Borrowings$6.0M$4.0M$3.0M$4.0M$3.0M

Latest News

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper GlobeNewswire · Jun 29, 2026 iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant GlobeNewswire · Jun 22, 2026 ​Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment Insider Monkey · Jun 19, 2026 Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry GlobeNewswire · Jun 16, 2026 IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-36.0M$-46.0M$-23.0M$-21.0M$-22.0M
Investing Cash Flow$-16.0M$-9.0M$-1.0M$-1.0M$-6.0M
Financing Cash Flow$2.0M$0$0$-2.0M$0
Net Cash Flow$28.0M$-14.0M$-12.0M$-1.0M$4.0M
Free Cash Flow$-38.0M$-50.0M$-24.0M$-21.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.17
EV / EBITDA-2.79
FCF Yield-16.47%
Quick Ratio1.25
Interest Coverage-399.72
Return 1Y57.04%
Return 3Y2.76%
Return 5Y-95.85%

Ownership

Insiders Held21.28%
Institutions Held60.78%
Institutions Float Held77.22%
Institutional HolderSharesReport Date
Broadwood Capital, Inc.11,931,8392026-03-31
AWM Investment Company, Inc.2,806,2562026-03-31
Pura Vida Investments, Llc947,1342026-03-31
Alyeska Investment Group, L.p.840,7772026-03-31
Vanguard Capital Management LLC537,1612026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
CDXS $1.47 -2.00% -5.06 $133.62M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
IVVD $0.55 +3.10% -3.53 $162.51M 0.00%

About Insight Molecular Diagnostics Inc.

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

Insight Molecular Diagnostics Inc. is led by CEO Joshua Riggs, employs 46 people, headquartered in US, publicly traded since 2015.

Insight Molecular Diagnostics Inc. (IMDX) stock trades at $4.70 with a market capitalization of $151.76M. The stock is valued at a price-to-earnings (P/E) ratio of -3.13, price-to-book of -15.30, price-to-sales of 78.53. Over the past 52 weeks the stock has ranged between $2.33 and $8.51, and currently trades 44.8% below its 52-week high.

On profitability, Insight Molecular Diagnostics Inc. generates a return on equity (ROE) of 380.80% — well above the market average, a sign of a high-quality business, return on capital employed of -144.86%, an operating margin of -775.00%, a net profit margin of -24.55%.

Official website: imdxinc.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides